sbryant89

sirna drug delivery nanotechnology biomarkers imaging cns parkinson’s disease pd neuro schizophrenia depression suicidality cns neuro 2010 alzheimer\'s disease ad dementia cognition trials clinical research clinical multiple sclerosis ms medcoms pharmacovigilance adherence mobile devices marketing smart health m-health anti-counterfeiting e-health smart phone e-pharma communication clinical trials medical devices physician mobile healthcare mhealth regulatory considerations oligonucleotide delivery classification safety and pricingreimbursement issues formulation nanopharmaceutical manufacturing engineering intellectual property mirna gene silencing rnai genetic anti-sense rna epigenetics oligonucleotides inflammatory disease mrna dsrna cardiovascular disease theraputics genomics developing portfolios resource allocation generics strategy ip research and development r&d pipeline pharmaceutical projects life cycle management optimisation portfolio integration lcm inhalatory biomaterials ocular polymers hot melt extrusion oral bioavailability peptides parenteral regulatory controlled release nasal sustained release